Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

MGCD-265 analog

Catalog No: tcsc0188

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
875337-44-3

Formula:
$C_{26}H_{20}FN_5O_2S_2$

Pathway:
Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:
c-Met/HGFR;VEGFR

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
517.6

Product Description

MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.

IC50 value:10 nM (VEGFR2), 29 nM(c-Met) [1]

Target:VEGFR, c-Met

in vivo: MGCD-265-analog has a reasonable half-life, 1.2 h in rats and 5.8 h in dogs, and has an acceptable clearance, 0.33 L/(kg h) in rats and 1.1 L/(kg h) in dogs. The steady state volume of distribution was low in rats (0.25 L/kg) and reasonable in dogs (1.5 L/kg), while the oral bio-availability was determined to be 12% and 42% in rats and dogs, respectively. GCD-265-analog performed well in vivo against a panel of different human tumor types, particularly those that are driven by or overexpress c-Met (MNNGHOS and MKN45). Tumor growth inhibition at a dose of 20 mg/kg po once daily ranged from 41% to 94%. MGCD-265-analog was found to show spill-over inhibition of a number of kinases in addition to the intended c-Met/VEGFR2 activity. MGCD-265-analog has significant antitumor activity in vivo.[1]